Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: A randomized controlled 1-year follow-up study

Nephrology Dialysis Transplantation

Volumn 27, Issue 3, 2012, Pages 1191-1199

  Park, Sun Hee ^a   Do, Jun Young ^b   Kim, Yeong Hoon ^c   Lee, Ho Yung ^d   Kim, Beom Seok ^d   Shin, Sug Kyun ^e   Kim, Hyun Chul ^f   Chang, Yoon Kyung ^g   Yang, Jong Oh ^h   Chung, Hyun Chul ⁱ   Kim, Chan Duck ^a   Lee, Won Kee ^j   Kim, Jong Yeon ^k   Kim, Yong Lim ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e National Health Insurance Corporation   (South Korea)

^f Keimyung University   (South Korea)

^g The Catholic University of Korea   (South Korea)

^h Soonchunhyang University   (South Korea)

ⁱ University of Ulsan College of Medicine   (South Korea)

^j Kyungpook National University School of Medicine   (South Korea)

^k Catholic University of Daegu   (South Korea)

more..

Author keywords

Endothelial dysfunction; Glucose degradation products; Inflammation; Peritoneal dialysis; Soluble adhesion molecules

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE DEGRADATION PRODUCT; INTERCELLULAR ADHESION MOLECULE 1; PERITONEAL DIALYSIS FLUID; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEMBRANE TRANSPORT; MULTICENTER STUDY; NUTRITIONAL STATUS; OPEN STUDY; OUTCOME ASSESSMENT; PERITONITIS; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; SURVIVAL RATE; SYSTEMIC DISEASE; THERAPY EFFECT; ULTRAFILTRATION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; DIALYSIS SOLUTIONS; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; GLUCOSE SOLUTION, HYPERTONIC; HUMANS; HYDROGEN-ION CONCENTRATION; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONITIS; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; TISSUE DISTRIBUTION; WATER-ELECTROLYTE BALANCE; YOUNG ADULT;

EID: 84861163875     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr451     Document Type: Article

References (32)

1. Lee HY, Park HC, Seo BJ et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25: 248-255
2. Han SH, Ahn SV, Yun JY et al. Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions. Am J Kidney Dis 2009; 54: 711-720
3. Danesh J, Collins R, Appleby P et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-1482
4. Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911
5. Zimmermann J, Herrlinger S, Pruy A et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658
6. Hwang SJ, Ballantyne CM, Sharrett AR et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-4225
7. Ridker PM, Hennekens CH, Roitman-Johnson B et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92
8. Papayianni A, Alexopoulos E, Giamalis P et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 2002; 17: 435-441
9. Stenvinkel P, Lindholm B, HeimburgerMet al. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000; 15: 1624-1630
10. Choi HY, Lee JE, Han SH et al. Association of inflammation and protein-energy wasting with endothelial dysfunction in peritoneal dialysis patients. Nephrol Dial Transplant 2010; 25: 1266-1271
11. Welten AG, Schalkwijk CG, ter Wee PM et al. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int 2003; 23: 213-221
12. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418
13. Schmitt CP, von Heyl D, Rieger S et al. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol Dial Transplant 2007; 22: 2038-2044
14. Lage C, Pischetsrieder M, Aufricht C et al. First in vitro and in vivo experiences with Stay-Safe Balance, a pH-neutral solution in a dualchambered bag. Perit Dial Int 2000; 20 (Suppl 5): S28-S32
15. La Milia V, Pozzoni P, Virga G et al. Peritoneal transport assessment by peritoneal equilibration test with 3.86% glucose: a long-term prospective evaluation. Kidney Int 2006; 69: 927-933
16. Keshaviah PR, Nolph KD, Moore HL et al. Lean body mass estimation by creatinine kinetics. J Am Soc Nephrol 1994; 4: 1475-1485
17. Randerson DH, Chapman GV, Farrell PC. Amino acid and dietary status in long-term CAPD patients. In: Atkins RC, Farrell PC, Thomson N, eds. Peritoneal Dialysis. Edinburgh, UK: Churchill Livingstone, 1981: 171-191
18. Choi HY, Kim DK, Lee TH et al. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int 2008; 28: 174-182
19. Szeto CC, Chow KM, Lam CW et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22: 552-559
20. Park SH, Lee EG, Kim IS et al. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat. Perit Dial Int 2004; 24: 115-122
21. Fusshoeller A, Plail M, Grabensee B et al. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 2004; 19: 2101-2106
22. Zeier M, Schwenger V, Deppisch R et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63: 298-305
23. Schmidt AM, Hori O, Chen JX et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-1403
24. Takahashi HK, Mori S, Wake H et al. Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 2009; 330: 89-98
25. Jacobson SH, Egberg N, Hylander B et al. Correlation between soluble markers of endothelial dysfunction in patients with renal failure. Am J Nephrol 2002; 22: 42-47
26. Linden E, Cai W, He JC et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol 2008; 3: 691-698
27. Reddy KG, Nair RN, Sheehan HM et al. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994; 23: 833-843
28. Haag-Weber M, Kramer R, Haake R et al. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 2010; 25: 2288-2296
29. Fan SL, Pile T, Punzalan S et al. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73: 200-206
30. Kim S, Oh J, Chung W et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009; 24: 2899-2908
31. Lupattelli G, Lombardini R, Schillaci G et al. Flow-mediated vasoactivity and circulating adhesion molecules in hypertriglyceridemia: association with small, dense LDL cholesterol particles. Am Heart J 2000; 140: 521-526
32. Vallbracht KB, Schwimmbeck PL, Seeberg B et al. Endothelial dysfunction of peripheral arteries in patients with immunohistologically confirmed myocardial inflammation correlates with endothelial expression of human leukocyte antigens and adhesion molecules in myocardial biopsies. J Am Coll Cardiol 2002; 40: 515-520